Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD)

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 8, 2013, Pages 1397-1404

  Spies Weisshart, Baerbel ^a   Schilling, Kristina ^a   Böhmer, Frank ^a   Hochhaus, Andreas ^a   Sayer, Herbert G ^a   Scholl, Sebastian ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Allogeneic PBSCT; Autoantibodies; Chronic GvHD; PDGF receptor

Indexed keywords

AUTOANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR AUTOANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIBODY DETECTION; APLASTIC ANEMIA; ARTICLE; CELL ASSAY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HODGKIN DISEASE; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

AUTOANTIBODIES; AUTOANTIGENS; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TRANSPLANTATION, HOMOLOGOUS;

EID: 84880917678     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1451-z     Document Type: Article

References (34)

1. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM (1989) Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 4:247-254
2. Ball LM, Egeler RM (2008) Acute GvHD: pathogenesis and classification. Bone Marrow Transplant 41(Suppl 2):S58-S64
3. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667-2676
4. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, Kashyap A, Flowers ME, Lilleby K, Chauncey TR, Storb R, Appelbaum FR (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175-181
5. Bjorklund A, Aschan J, Labopin M, Remberger M, Ringden O, Winiarski J, Ljungman P (2007) Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant 40:1055-1062
6. Chakraverty R, Mackinnon S (2011) Allogeneic transplantation for lymphoma. J Clin Oncol official J Am Soc ClinOncol 29:1855-1863
7. Choi SW, Levine JE, Ferrara JL (2010) Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am 30:75-101
8. Chu YW, Gress RE (2008) Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 14:365-378
9. Classen JF, Henrohn D, Rorsman F, Lennartsson J, Lauwerys BR, Wikstrom G, Rorsman C, Lenglez S, Franck-Larsson K, Tomasi JP, Kampe O, Vanthuyne M, Houssiau FA, Demoulin JB (2009) Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 60:1137-1144
10. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R (2004) Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 10:178-185
11. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Investig 114:1308-1316
12. Ferrara JL, Reddy P (2006) Pathophysiology of graft-versus-host disease. Semin Hematol 43:3-10
13. Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373:1550-1561
14. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME (2005) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 11:945-956
15. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI, Storb R, Appelbaum FR, Forman SJ, Blume KG, Martin PJ (2002) Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100:415-419
16. George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K (2010) Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis official J Transplant Soc 12:322-329
17. Jagasia MH, Savani BN, Stricklin G, Engelhardt B, Kassim A, Dixon S, Chen H, Chinratanalab W, Goodman S, Greer JP, Schuening F (2009) Classic and overlap chronic graft-versus-host disease (cGVHD) is associated with superior outcome after extracorporeal photopheresis (ECP). Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 15:1288-1295
18. Kier P, Penner E, Bakos S, Kalhs P, Lechner K, Volc-Platzer B, Wesierska-Gadek J, Sauermann G, Gadner H, Emminger-Schmidmeier W et al (1990) Autoantibodies in chronic GVHD: high prevalence of antinucleolar antibodies. Bone Marrow Transplant 6:93-96
19. Leder C, Ortler S, Seggewiss R, Einsele H, Wiendl H (2007) Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol 35:1266-1271
20. Lister J, Messner H, Keystone E, Miller R, Fritzler MJ (1987) Autoantibody analysis of patients with graft versus host disease. J Clin Lab Immunol 24:19-23
21. Loizos N, Lariccia L, Weiner J, Griffith H, Boin F, Hummers L, Wigley F, Kussie P (2009) Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 60:1145-1151
22. Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L, Jouet JP, Yakoub-Agha I (2009) Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 114:719-722
23. Markova B, Herrlich P, Ronnstrand L, Bohmer FD (2003) Identification of protein tyrosine phosphatases associating with the PDGF receptor. Biochemistry 42:2691-2699
24. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R (2003) Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102:756-762
25. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, Gini G, Mordini N, Balduzzi A, Leoni P, Gabrielli A, Bacigalupo A (2009) Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 114:709-718
26. Osumi T, Miharu M, Tanaka R, Du W, Takahashi T, Shimada H (2012) Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD. Bone Marrow Transplant 47:139-140
27. Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, Cutler C, Jacobsohn D, Palmer J, Arai S, Jagasia M, Lee SJ (2011) Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 117:4651-4657
28. Remberger M, Ackefors M, Berglund S, Blennow O, Dahllof G, Dlugosz A, Garming-Legert K, Gertow J, Gustafsson B, Hassan M, Hassan Z, Hauzenberger D, Hagglund H, Karlsson H, Klingspor L, Kumlien G, Le Blanc K, Ljungman P, Machaczka M, Malmberg KJ, Marschall HU, Mattsson J, Olsson R, Omazic B, Sairafi D, Schaffer M, Svahn BM, Svenberg P, Swartling L, Szakos A, Uhlin M, Uzunel M, Watz E, Wernerson A, Wikman A, Wikstrom AC, Winiarski J, Ringden O (2011) Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 17:1688-1697
29. Rowe JM (2011) Interpreting data on transplant selection and outcome in adult acute lymphoblastic leukemia (ALL). Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 17:S76-S83
30. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763
31. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T et al (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250-259
32. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, Moroncini G, Bacigalupo A, Leoni P, Avvedimento EV, Gabrielli A (2007) Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110:237-241
33. Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic SZ, Greinix H, Holler E (2011) Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 17:1-17
34. Zerr P, Distler A, Palumbo-Zerr K, Tomcik M, Vollath S, Dees C, Egberts F, Tinazzi I, Del Galdo F, Distler O, Schett G, Spriewald BM, Distler JH (2012) Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease. Am J Pathol 181:1672-1680